Biomedical Bonding has received a granted patent from the United States Patent and Trademark Office (USPTO). The invention relates to a primer composition that may be applied to tissue to increase bond strength between the tissue and a patch, filler, or a
supporting material. The primer comprises a dithiol component and an allyl containing component together with a photo initiator.
The primer is an important part of ™
Our IP protection is now broader and targets key geographical areas. We look forward to introducing our appreciated novel technology to the US market”, comments Evelina Mikaelson CEO Biomedical Bonding
![Biomedical Bonding has received a granted patent from the United States Patent and Trademark Office (USPTO).](https://static.wixstatic.com/media/27f684_08e7d8389db4420fa540d2b7ca9ccd0c~mv2.jpg/v1/fill/w_147,h_98,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/27f684_08e7d8389db4420fa540d2b7ca9ccd0c~mv2.jpg)
For more information, please contact.
Evelina Mikaelson
CEO Biomedical Bonding AB
Phone:+46 763 422 824
Homepage: www.biomedicalbonding.com
About Biomedical Bonding AB
Biomedical Bonding AB is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.